ArticleMethods in molecular biology (Clifton, N.J.)2009
Expression of single-chain Fv fragments in E. coli cytoplasm.
Article in Methods in molecular biology (Clifton, N.J.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Enhancing soluble expression and purification of a bispecific scFv antibody inResearch in pharmaceutical sciences · 2026Article
- The Production and Purification of Therapeutic Antibodies: A Comprehensive Analysis of Process- and Product-Related Contaminants.Biomolecules · 2026Review
- Comparative evaluation of E. coli expression systems for soluble hScFv-IL-17A with an unpaired CDR-L3 cysteine.Journal, genetic engineering & biotechnology · 2025Article
- Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies.Research in pharmaceutical sciences · 2025Article
- Production of a Soluble Recombinant Antibody Fragment against MMP9 UsingMedicina (Kaunas, Lithuania) · 2021Article
- Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): AnIranian journal of basic medical sciences · 2021Article
- Anti-HER2 scFv Expression in Escherichia coli SHuffleMolecular biotechnology · 2020Article
- Design and Production of Bispecific Antibodies.Antibodies (Basel, Switzerland) · 2019Review
- The production of a recombinant tandem single chain fragment variable capable of binding prolamins triggering celiac disease.BMC biotechnology · 2018Article
- Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.Journal of nanobiotechnology · 2017Article
- A transcription activator-like effector (TALE) induction system mediated by proteolysis.Nature chemical biology · 2016Article
- High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Microbial cell factories · 2013Article
- Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.Cellular and molecular biology (Noisy-le-Grand, France) · 2012Article
- The use of phage display to generate conformation-sensor recombinant antibodies.Nature protocols · 2012Article
- Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.Retrovirology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most frequently used approach to produce single-chain Fv fragments (scFv) and Fab in Escherichia coli is to express them in the periplasm of the bacteria. We present here an alternative procedure that uses cytoplasmic expression of soluble active scFv. This can be accomplished by using either specially engineered E. coli strains or hyperstable scFvs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.